Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of March 2025. The filing details a share repurchase executed on March 19, 2025, pursuant to a non-discretionary agreement with Citigroup Global Markets Limited entered into on February 24, 2025.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on capital structure changes via share buybacks and does not report operational financial metrics such as revenue, profit, cash flow, or debt levels.
- Shares Purchased (March 19, 2025): 556,200 ordinary shares.
- Price Range: Lowest price paid was 1,493.50p; highest price paid was 1,520.00p.
- Volume-Weighted Average Price (VWAP): 1,512.27p.
- Trading Venue: London Stock Exchange (XLON).
- Treasury Shares Held: 181,384,970 ordinary shares following this transaction.
- Shares in Issue: 4,133,820,322 ordinary shares (excluding Treasury shares).
- Total Voting Rights: 4,133,820,322.
Material Changes Versus Prior Period
Since the commencement of the current buyback programme on February 24, 2025, the Company has purchased an aggregate of 12,314,667 ordinary shares. The filing does not provide comparative financial data for prior periods as it is a transaction-specific report rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the Risk Factors section (pages 277 to 285) of the GSK 2024 Annual Report on Form 20-F.
Important Facts for Investor Verification
- Verify the total number of shares in issue (4,133,820,322) to calculate ownership percentages under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
- Confirm the cumulative buyback volume of 12,314,667 shares since February 24, 2025, to assess the remaining capacity of the current programme.
- Note that the purchased shares are held as Treasury shares and do not carry voting rights.
- Review the GSK 2024 Annual Report on Form 20-F for detailed risk factors associated with the Company's operations and forward-looking statements.